Industry & Trends

Retatrutide is not FDA approved for any indication and remains strictly an investigational compound. Currently undergoing Phase 3 clinical trials, […]

A 2026 landscape report on the research-peptide compound classes drawing the most laboratory attention — from multi-receptor metabolic agonists to mitochondrial-derived peptides — and what is driving each one’s research momentum.

A category-level overview of metabolic research peptides — incretin-pathway compounds like Retatrutide, mitochondrial-derived peptides like MOTS-c, and NAD+ pathway compounds — for laboratory and in-vitro research audiences.

A scientific-journalist survey of the GLP-1 peptides research landscape — from semaglutide’s single-receptor origins to tirzepatide’s dual-agonist era to retatrutide’s triple-agonist research profile, framed strictly for laboratory and in-vitro research use.